By Fineline Cube Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced that its Category 1 chemical drug APH03867 Tablets has received clinical trial approval from China’s National Medical Products Administration (NMPA) for the treatment of gout patients with hyperuricemia, advancing a novel oral URAT1 inhibitor into a market with high and growing prevalence in China.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval |
| Drug Category | Category 1 chemical drug |
| Product | APH03867 Tablets |
| Indication | Gout patients with hyperuricemia |
| Sponsor | Yipinhong Pharmacy Co., Ltd. (SHE: 300723) |
| Announcement Date | 21 Aug 2026 |
Drug Profile & Mechanism of Action
- Molecule: Novel oral, non-peptide small-molecule inhibitor of URAT1 (Urate Transporter 1)
- Mechanism: Inhibits URAT1 activity in the kidneys → blocks urate reabsorption in renal tubules → increases uric acid excretion → effectively lowers blood uric acid levels
- Therapeutic Effect: Improves hyperuricemia and gout symptoms
- Target Significance: URAT1 accounts for approximately 90% of renal urate reabsorption, making it a key therapeutic target for gout and hyperuricemia
Market Impact & Outlook
- Large Patient Base: China has one of the world’s largest gout and hyperuricemia populations, driven by dietary and metabolic trends, giving urate-lowering therapies a substantial addressable market.
- Mechanistic Fit: As a uricosuric agent blocking ~90% of renal urate reabsorption, APH03867 offers a complementary option to xanthine oxidase inhibitors that dominate current treatment, particularly for patients with inadequate response or intolerance.
- Category 1 Positioning: Category 1 status designates APH03867 as a globally novel compound, giving Yipinhong potential for differentiated intellectual property and premium positioning in a largely generic-dominated urate-lowering space.
- Next Milestones: Investors will watch for first-in-human trial initiation, safety and pharmacokinetic readouts, and subsequent dose-optimization and efficacy data in hyperuricemia patients.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory timelines and commercial potential of APH03867. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements and competitive dynamics in gout and hyperuricemia therapeutics.-Fineline Info & Tech